Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04
12
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
To study the toxicity, pharmacokinetics, and antiretroviral effectiveness of combined oral zidovudine (AZT) and intermittent intravenous foscarnet therapy in stable AIDS or AIDS related complex (ARC) patients who have already received AZT for 8 - 52 weeks.
It is hypothesized that the maximum AZT antiretroviral effect, which occurs at 8 weeks of therapy, will be enhanced by 2 weeks of foscarnet treatment, given at the same time by intermittent intravenous infusion. In addition, the further lowering of serum p24 antigen concentration that should occur during combined therapy might continue when oral AZT therapy is continued without foscarnet.
CONDITIONS
Brief Title
A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
Medication necessary for the patient's welfare at the discretion of the investigator.
Patients must have the following:
Received zidovudine (AZT) 200 mg every 4 hours (q4h) continuously for 8 - 16 weeks without Grade 3 or higher toxicity.
Detectable p24 antigen in serum on at least 2 occasions during the prestudy period. All serum p24 antigen concentrations measured during the prestudy period must be at least twice the concentration cutoff value of the assay.
Capability of giving informed consent.
Per amendment of 890721, patients must enter the study period by September 30, 1989.
Exclusion Criteria
Co-existing Condition:
Patients with the following will be excluded:
A history of hypersensitivity reaction to foscarnet or zidovudine (AZT).
History of Grade 3 or 4 toxicity with AZT.
Current Grade 2 or higher AZT toxicity.
Osteomalacia, neoplasm metastatic to bone, or other known bone disease.
Active opportunistic infection requiring myelosuppressive or nephrotoxic therapy.
Concurrent Medication:
Excluded:
Antimetabolites.
Immunomodulators.
Nephrotoxins.
Antiviral therapy.
Myelosuppressive or nephrotoxic therapy.
Acetaminophen.
Patients with the following will be excluded:
A history of hypersensitivity reaction to foscarnet or zidovudine (AZT).
History of Grade 3 or 4 toxicity with AZT.
Current Grade 2 or higher AZT toxicity.
Osteomalacia, neoplasm metastatic to bone, or other known bone disease.
Active opportunistic infection requiring myelosuppressive or nephrotoxic therapy.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Long-term Follow-up Study of Adults with HIV Previously in HIV-NAT Trials
Observing Safety, Treatment Effects, and Quality of Life
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Comparing Cabotegravir Ultra Long-Acting Plus Rilpivirine Ultra Long-Acting Versus Long-Acting Cabotegravir and Rilpivirine in Teens and Adults With Controlled HIV
Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of Long-Acting Cabotegravir with Recombinant Human Hyaluronidase PH20 in Healthy Adults Aged 18 to 55
Phase 1 Study to Assess Safety, Tolerability, and Drug Behavior of VH4770359 in Healthy Adults Aged 18 to 55
Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).